Medtronic Stock Price, News & Analysis

Medtronic (MDT), a global healthcare technology leader, partnered with Jack and Jill of America, Inc., a nonprofit focused on nurturing future African American leaders, to provide hands-on healthcare technology experiences to over 150 teens at Jack and Jill's national convention. The event featured the Medtronic Mobile Lab, a truck designed to mirror an operating room, where students had the opportunity to use surgical tools. This initiative aims to expose young people to potential careers in healthcare technology and foster interest in the field.

Medtronic (MDT) has been recognized as a 'Best Place to Work for Disability Inclusion' for the seventh consecutive year in the U.S. and for the first time in the U.K. by Disability:IN and the American Association of People with Disabilities. The company earned a top score of 100 on the 2024 Disability Equality Index®, the world's most comprehensive benchmarking tool for measuring disability workplace inclusion.

This recognition, along with Medtronic's ranking among DiversityInc's 2024 Top Companies for People with Disabilities, validates the company's commitment to employees with disabilities and their allies. Medtronic's focus on inclusion, diversity, and equity (ID&E) aims to create a culture where all employees belong, are respected, and feel valued. This approach not only enhances employee well-being but also accelerates innovation in lifesaving technologies.

Medtronic announced on June 26, 2024, that Karen Parkhill, its Chief Financial Officer, will resign to join HP as CFO. Parkhill will remain in her role until August 2, 2024, after which Gary Corona, SVP of Global Financial Planning, will serve as interim CFO. CEO Geoff Martha expressed gratitude for Parkhill's eight years of leadership, particularly during the pandemic and the company's recent transition to a new operating model. The company reassured stakeholders by reaffirming its financial guidance for Q1 and the full fiscal year 2025.

Medtronic presented new data on the MiniMed™ 780G system at the American Diabetes Association's 84th Scientific Sessions, highlighting its effectiveness in managing type 1 diabetes. The data demonstrated significant improvements in reducing early morning hyperglycemia, known as dawn phenomenon, and enhancing overnight sleep quality. Users of the MiniMed™ 780G system experienced a decrease in dawn phenomenon rates from 12.2% to 4.5%, and a 45% reduction in nighttime alerts. Time in Range (TIR) increased from 87.7% to 91.4% during the critical hours of 12-6 a.m. The system's advanced algorithm provides autocorrections every 5 minutes, significantly reducing the burden of diabetes management. Additionally, promising results were presented for the next iteration of the system, paired with the Simplera Sync™ sensor, showing improvements in clinical outcomes. The new system will be launched in parts of Europe in late July.

Sempra (NYSE: SRE) has appointed Jennifer M. Kirk to its board of directors, effective June 20, 2024. Kirk currently serves as the global controller and chief accounting officer at Medtronic (NYSE: MDT) and brings over 20 years of experience in the energy sector. Her previous roles include various senior positions at Occidental Petroleum Kirk also chairs the audit committee at Republic Services. With her appointment, Sempra's board now has 10 directors, including three new members added over the past five years. Kirk will be a member of the audit and the safety, sustainability, and technology committees.

BetterInvesting Magazine has announced Amphastar Pharmaceuticals (NASDAQ: AMPH) as its 'Stock to Study' and Medtronic (NYSE: MDT) as its 'Undervalued Stock' for the September 2024 issue. The National Association of Investors Corp. (NAIC) encourages investors to focus on fundamentals and informed decision-making. The magazine's choices are informational and educational, not endorsements. A trial version of BetterInvesting's tools is available for non-members to analyze these stocks. The committee includes several CFA members who review the stocks, emphasizing investor education. Full details will be available in the magazine's September issue.

Medtronic LABS has released a documentary titled 'Better Health for Everyone, Everywhere,' showcasing their healthcare technology's impact on underserved communities. It follows Jane Muthoni, who, diagnosed with diabetes during her childhood, now travels across Africa to educate others on managing conditions like diabetes and high blood pressure. The documentary highlights the important role of Medtronic LABS in providing essential health services to over half the world's population that currently lacks access. The initiative aims to improve health outcomes by leveraging healthcare technology to reach more communities.

Medtronic (NYSE: MDT) chairman and CEO Geoff Martha is scheduled to speak at the 45th annual Goldman Sachs global healthcare conference on June 11, 2024. The Q&A session will start at 10:40 a.m. EDT and will be available via a live webcast. An archive will be accessible later on the company's investor relations webpage.

Medtronic, headquartered in Dublin, Ireland, is a leading global healthcare technology company. It operates in over 150 countries with a workforce of more than 95,000. The company offers innovative solutions across 70 health conditions including cardiac devices, surgical robotics, and insulin pumps. Medtronic is committed to alleviating pain, restoring health, and extending life.

Medtronic has closed a €3.0 billion public offering of senior notes. The offering includes €850 million of 3.650% notes due 2029, €850 million of 3.875% notes due 2036, €600 million of 4.150% notes due 2043, and €700 million of 4.150% notes due 2053. The net proceeds, approximately €2.97 billion, will be used for general corporate purposes, including debt repayment. The notes are guaranteed by Medtronic and Medtronic Global Holdings S.C.A. Citigroup, J.P. Morgan, Merrill Lynch, and Mizuho led the offering, with several other firms acting as co-managers.